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PURPOSE: To fabricate microcontainers in either SU-8 or biodegradable poly-L-lactic acid (PLLA), and fill the 
microcontainers with either poorly soluble drugs or vaccine formulations. Furthermore, the application of 
the microcontainers as an oral drug delivery system was investigated in terms of release and oral 
bioavailability in rats.  
METHODS: SU-8 microcontainers were fabricated using two steps of photolithography, whereas PLLA 
microcontainers were prepared by hot embossing. In terms of drug filling, the SU-8 microcontainers were 
filled with polyvinylpyrrolidone (PVP) by inkjet printing followed by supercritical CO2 impregnation of 
ketoprofen into the PVP matrix. As one of the alternative filling methods, the powder of amorphous sodium 
salt of furosemide, (ASSF) was filled into the SU-8 microcontainers. The PLLA microcontainers were filled 
with drug formulation by embossing the microcontainers into a polycaprolactone (PCL) and furosemide (4:1 
w/w) layer. Furthermore, the embossing method also made it possible to load the SU-8 microcontainers 
with a mixture of budesonide, Soluplus® and polyethylene glycol (PEG) and likewise with powder of 
cubosomes intended for oral vaccine delivery. For both the ASSF-filled microcontainers and the ketoprofen-
loaded microcontainers, an enteric-resistant lid of Eudragit® L100 was spray coated onto the cavity of the 
microcontainers. Release of ASSF or of ketoprofen from the coated microcontainers was investigated in 
simulated intestinal medium at pH 6.5. For the in vivo studies, the rats were dosed orally with capsules 
containing ASSF-filled microcontainers coated with Eudragit® L100. As control, capsules were filled with the 
powder of ASSF and the capsules were coated with Eudragit® L100.  
RESULTS: The SU-8 microcontainers had an inner diameter of 220 µm and a cavity depth of 270 µm, and for 
the PLLA microcontainers the inner diameter was found to be 240 µm and with a cavity depth of 65 µm. 
The microcontainers were successfully filled with either PVP:ketoprofen (Figure 1a), ASSF, PCL:furosemide, 
budesonide:Soluplus:PEG or cubosomes (Figure 1b). A fast release of ASSF (88% within 3h) or ketoprofen 
(100% within 6 h) from the microcontainers was observed and the Eudragit coating was shown not to be a 
hindrance for rapid release at intestinal conditions. The oral bioavailability study demonstrated that the 
relative oral bioavailability of ASSF in microcontainers was 220±43% when compared to drug-filled capsules 
coated with Eudragit. This was reflected by a larger area below the curve for the ASSF in microcontainers 
(Figure 2).   
CONCLUSIONS: Both SU-8 and biodegradable PLLA microcontainers were successfully fabricated and 
loaded with poorly soluble drugs or vaccine formulation (cubosomes). A fast release of ASSF was facilitated 
from the SU-8 microcontainers. Furthermore, using the microcontainers resulted in a higher oral 
bioavailability when compared to non-confined ASSF. The fabricated microcontainers therefore show 
considerable future potential as oral drug delivery systems. 
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Figure 1: SEM images of microcontainers filled with a)
PVP and CO2 impregnated ketoprofen and b)
cubosomes intended for oral vaccine delivery
Figure 2: Plasma concentrations of microcontainers filled with ASSF coated 
with Eudragit® L100 and filled into capsules and ASSF dosed in capsules 
with Eudragit coating after orally dosing to rats 
